Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinnaining Capsule in post-ACS patients with carotid plaque and residual inflammatory risk
ChiCTR1900025832Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xinnaining Capsule in acute coronary syndrome (ACS), coronary arteriosclerosis, angina pectoris and 1 more (2 arms), sponsored by Affiliated Hospital of Shandong University of Traditional Chinese Medicine. Primary endpoints: Dynamic electrocardiography and High-sensitivity C-reactive protein. Started Dec 2018; status: recruiting.
02
Drugs
Xinnaining Capsule
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosisangina pectoriscarotid atheroma (CAS)
Beyond the preview
Go deeper on ChiCTR1900025832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025832.